GSK's injectable antisense drug, given for a limited period alongside standard antivirals, is cleared for selected adults with low surface-antigen levels and carries a boxed safety warning. The U.S. Food and Drug Administration today approved Hibsago (bepirovirsen) injection, in combination…
Continue reading with a subscription
This article is available to subscribers. Subscribe to read it in full, or sign in if you already have an account.